Clovis Oncology Inc (CLVS) was Downgraded by Credit Suisse to ” Neutral”. Earlier the firm had a rating of “Outperform ” on the company shares. Credit Suisse advised their investors in a research report released on Apr 13, 2016.
Many Wall Street Analysts have commented on Clovis Oncology Inc. Shares were Reiterated by Mizuho on Apr 13, 2016 to “Neutral” and Lowered the Price Target to $ 15 from a previous price target of $21 .Clovis Oncology Inc was Downgraded by JP Morgan to ” Neutral” on Apr 13, 2016. Clovis Oncology Inc was Resumed by Piper Jaffray to “Neutral” on Apr 4, 2016.
On the company’s financial health, Clovis Oncology Inc reported $-3.12 EPS for the quarter, missing the analyst consensus estimate by $ -0.68 based on the information available during the earnings call on Feb 25, 2016. Analyst had a consensus of $-2.44.During the same quarter in the previous year, the company posted $-1.62 EPS.
Clovis Oncology Inc closed down -0.71 points or -4.50% at $15.06 with 47,51,051 shares getting traded on Monday. Post opening the session at $15.97, the shares hit an intraday low of $14.375 and an intraday high of $16.05 and the price fluctuated in this range throughout the day.Shares ended Monday session in Red.
In a different news, on Nov 3, 2015, Erle T Mast (Executive VP and CFO) sold 3,000 shares at $104.18 per share price. According to the SEC, on Oct 30, 2015, Lindsey Rolfe (officer ) sold 4,000 shares at $97.80 per share price. On Oct 16, 2015, Gillian C Ivers-read (officer ) sold 3,000 shares at $91.91 per share price, according to the Form-4 filing with the securities and exchange commission.
Clovis Oncology Inc. (Clovis) is a biopharmaceutical company focused on acquiring developing and commercializing anti-cancer agents in the United States Europe and additional international markets. The Company is developing three product candidates: Rociletinib Rucaparib and Lucitanib. Rociletinib an oral epidermal growth factor receptor (EGFR) is a mutant-selective covalent inhibitor that is in advanced clinical development for the treatment of non-small cell lung cancer. Rucaparib an oral inhibitor of poly (ADP-ribose) polymerase (PARP) is in advanced clinical development for the treatment of ovarian cancer. Lucitanib is an oral potent inhibitor of the tyrosine kinase activity of fibroblast growth factor receptors 1-3 (FGFR1-3) vascular endothelial growth factor receptors 1-3 (VEGFR1-3) and platelet-derived growth factor receptors alpha and beta (PDGFR a/B) that is in Phase II development for the treatment of breast and lung cancers.